After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml ...

The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...

Icelandic biotechnology company Alvotech intends to explore the possibility of a Stockholm listing as it announced the acquisition of a Swedish research and development operation and drug candidate.

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Thursday announced the acquisition of Xbrane Biopharma AB’s R&D operations and a biosimilar candidate, establishing a footprint in the Swedish life science sector.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.

Dr. Reddy’s (RDY) and Alvotech (ALVO) announced that the FDA has accepted a 351(k) biologic license application submission for AVT03, developed ...

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ: ALVO), a global biotech ...

Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. Food and Drug Administration, FDA, has accepted a 351(k) Biologic ...